Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
IO-202 by Immune Onc Therapeutics for Solid Tumor: Likelihood of Approval
IO-202 is under clinical development by Immune Onc Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData,...
Data Insights
IO-202 by Immune Onc Therapeutics for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
IO-202 is under clinical development by Immune Onc Therapeutics and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According...